H.B. Fuller's (FUL) 2026 outlook remains conservative and beatable, although the planned acquisition of Advanced Medical Solutions is expected to weigh on the stock's valuation in the near term because of higher leverage, UBS said in a note emailed Friday.

The brokerage said it expects pricing realization likely to determine whether the company exceeds the upper end of its outlook.

"We continue to see the 2H26 outlook for FUL as conservative and beatable," UBS said. "We expect the acquisition of AMS to be a headwind to FUL's trading multiple in the short term," it added.

UBS cut its price target to $69 from $71 and maintained its neutral rating.

Price: 61.31, Change: -0.64, Percent Change: -1.03